By 2030, there will be 1 billion people over 65 years of age worldwide compared to 600 million currently, and healthcare must adjust to this changing demography. In addition, we are faced with multiple unmet medical needs and healthcare costs are rising globally. As a consequence several adaptations are necessary, including new therapeutic options, shortened in-patient hospital stays, increased outpatient care and more self-administration of drugs.
The Central Nervous System (CNS) drug market is of interest as it comprises several areas, some with high unmet medical needs, such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, migraine, insomnia, ADHD (Attention Deficiency Hyperactivity Disorder), anxiety disorders and bipolar disorder. In 2015, the drug market for CNS was valued at $143 billion.
Nasal drug delivery devices can play a role in meeting some of these unmet medical needs, and an area within drug delivery generating much attention is the possibility of treating CNS diseases by the so-called "nose-to-brain" route.
Speakers will cover several subjects related to the CNS market from different perspectives. A detailed review of the advantages of nasal drug delivery in relation to the unmet needs in the CNS market will be presented. The options available and the comparative technical merits of nasal devices will be discussed and Aptar Pharma will share their know-how gained from more than 30 years of experience in this specialized drug delivery field. Finally the speakers will look into the future and explore how some of these CNS diseases could possibly be treated via the nose-to-brain pathway.
Anyone interested in the growing area of CNS therapy who is considering using nasal drug delivery to find solutions for patients will benefit strongly from participating in this webinar.
Pierre Carlotti,
VP Marketing Communication
Pierre is a member of Aptar Pharma’s Management Committee. He’s responsible for all aspects of marketing and communication, from marketing plans and innovation roadmaps to new business branding, technical and scientific partnerships, and, more recently, connected health programs, for the Prescription Division and, since 2013, the Injectables Division. Pierre has a postgraduate degree in Biology and is an ISCE-Paris Business School graduate. Prior to joining Aptar, Pierre worked at Sanofi and West Pharmaceutical Services.
Dr. Julie Suman,
President
Julie is co-founder and President of Next Breath, LLC, a specialty company of Aptar Pharma. She holds a B.S. in Pharmacy from Duquesne University and a Ph.D. in Pharmaceutical Sciences from the University of Maryland. She is an adjunct assistant professor at the University of Maryland and an Affiliate Assistant Professor at Virginia Commonwealth University. Her doctoral research, focusing on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by an ISAM research award.
Dr. Gerallt Williams,
Director Scientific Affairs
After obtaining his Ph.D. from the University of Wales, UK in 1985, Gerallt has held various industrial positions at Monsanto Inc. (UK), Fisons Ltd (UK), Valois (France) and Inhale/Nektar Therapeutics (USA).
Gerallt is now in charge of scientific affairs for the Aptar Pharma Prescription division, Le Vaudreuil, France and is engaged in the development of new devices for nasal, inhaled and injectable drug products.
- Learn about unmet medical needs and market opportunities for nasal drug delivery to treat CNS diseases
- Increased understanding of nasal drug delivery devices that target CNS related diseases
- A look at where the future might be heading with new opportunities in areas such as nose-to-brain drug delivery
- Research & Development
- Academic Researchers
- Packaging
- Laboratory Testing
- Sales & Marketing
- Business Development
- Project Managers
- Product Managers
